Search

everythinglearnresearchcommunity

for

Search:↓

The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

The user has been using finasteride for 9 months, which initially stopped hair loss, but recently hair loss has resumed. They are considering switching to dutasteride.

A user experienced increased pimples and cysts after two years on dutasteride, possibly due to hormonal changes. Suggestions included seeing an endocrinologist, using supplements like boron and DIM, adjusting diet, and reducing body fat to manage side effects.

The user has been on dutasteride for three years but is still experiencing hair recession and is considering adding finasteride. Suggestions include trying minoxidil, microneedling, or a hair transplant for further improvement.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user inquires if RENU Biogen is a DHT inhibitor.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

A 26-year-old male has been using dutasteride for one year after previously using finasteride, along with 5% minoxidil and micro-needling, to treat hair loss. He reports no side effects and is satisfied with the progress, noting some shedding as part of the hair cycle.

Some users experience worsening hair loss with dutasteride, while others improve after initial shedding. Many switch back to finasteride due to better results or fewer side effects, often using minoxidil and topical treatments.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

A 19-year-old male experienced hair shedding after one year on dutasteride and is considering adding topical minoxidil despite scalp itching. Users suggest continuing dutasteride, maintaining a consistent hair routine, and possibly increasing minoxidil dosage.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

A user experienced no reduction in DHT levels after 8 months of finasteride, despite initial improvement in hair loss. They are considering switching to dutasteride but are concerned about potential side effects.

Woman uses antiandrogens for hair thinning prevention, experiences severe dry eye with finasteride. Asks if dutasteride could be better despite potential for worse dry eye.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The user regrets not continuing hair loss treatment with finasteride earlier and plans to restart it along with minoxidil. Another user suggests trying dutasteride and oral minoxidil as a more effective treatment.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.

The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.

Creatine may cause increased hair shedding due to androgen receptor sensitivity, despite limited evidence. The user is using dutasteride and minoxidil and seeks advice on whether shedding will stabilize, with suggestions including GHK-Cu and RU58841.

A 28-year-old male with severe hair loss is considering switching from finasteride to dutasteride due to side effects from oral finasteride, despite using topical minoxidil and finasteride with minimal improvement. He seeks advice on whether dutasteride might be effective without affecting libido.

The user tried Dutasteride, Finasteride, and Minoxidil for hair loss but saw no improvement after nearly two years, feeling frustrated and considering giving up. Other users suggested trying different dosages, oral Minoxidil, RU58841, or considering a hair transplant, while some noted that stabilization without regrowth is common.

Dutasteride can lead to increased cholesterol and liver fat. The user is reconsidering its use due to high cholesterol and lipid levels despite a healthy lifestyle.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.

A 31-year-old male switched from finasteride to oral dutasteride (0.5mg, 2x a week) and uses liquid minoxidil daily for hair loss. He experienced shedding and regrowth but is considering increasing dutasteride to 3x a week due to concerns about hair density and ongoing issues.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.